Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab
- 5 February 2021
- journal article
- letter
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 87 (1), 119-121
- https://doi.org/10.4103/ijdvl.ijdvl_671_19
Abstract
IJDVL is an peer-reviewed biomedical periodical of Indian Association of Dermatologists, Venereologists and Leprologists.Keywords
This publication has 5 references indexed in Scilit:
- IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center ExperienceActa Dermato-Venereologica, 2019
- Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case seriesBritish Journal of Dermatology, 2019
- Interleukin‐17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbiditiesExperimental Dermatology, 2017
- Psoriasis and comorbid diseasesJournal of the American Academy of Dermatology, 2017
- Psoriasis and comorbid diseasesJournal of the American Academy of Dermatology, 2017